Management of corticosteroid-induced osteoporosis (Q33857195)

29 July 2017

1 reference

title

Management of corticosteroid-induced osteoporosis. (English)

1 reference

29 July 2017

0 references

J D Adachi

1 reference

29 July 2017

W P Olszynski

1 reference

29 July 2017

D A Hanley

1 reference

29 July 2017

A B Hodsman

1 reference

29 July 2017

D L Kendler

1 reference

29 July 2017

K G Siminoski

1 reference

29 July 2017

J Brown

1 reference

29 July 2017

E A Cowden

1 reference

29 July 2017

D Goltzman

1 reference

29 July 2017

G Ioannidis

1 reference

29 July 2017

R G Josse

1 reference

29 July 2017

L G Ste-Marie

1 reference

29 July 2017

A M Tenenhouse

1 reference

29 July 2017

K S Davison

1 reference

29 July 2017

K L Blocka

1 reference

29 July 2017

A P Pollock

1 reference

29 July 2017

J Sibley

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Seminars in Arthritis and Rheumatism

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

228-251

1 reference

Corticosteroid effects on proximal femur bone loss

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Steroid-induced fractures and bone loss in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Generalised bone loss in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of short-term glucocorticoids on serum osteocalcin in healthy young men.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

The course of biochemical parameters of bone turnover during treatment with corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Low serum osteocalcin levels in glucocorticoid-treated asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Corticosteroid and bone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of Glucocorticoids on Function of the Parathyroid Glands in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Calcium and phosphorus homeostasis in man. Effect of corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effects of 1,25-dihydroxycholecalciferol on intestinal calcium transport in cortisone-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Corticosteroids and osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

1 reference

7 January 2021

The assessment of the systemic effects of inhaled glucocorticosteroids. The effects of inhaled budesonide vs oral prednisolone on calcium metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Short-term effects of 1-alpha-hydroxy-vitamin D3 in patients on corticosteroid treatment and in patients with senile osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Unanticipated stimulatory action of glucocorticoids on epithelial calcium absorption. Effect of dexamethasone on rat distal colon

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

The intestinal handling of calcium by the rat in vivo, as affected by cortisol. Effect of dietary calcium supplements

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Reduction of serum-1, 25-dihydroxyvitamin-D3 in children receiving glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Inhibition of Luteinizing Hormone Secretion Induced by Synthetic LRH by Long-term Treatment with Glucocorticoids in Human Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Reversible gonadotropin Deficiency in Male Cushing's Dusease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Cortisol-induced suppression of plasma testosterone in normal adult males

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Reduction of serum testosterone levels during chronic glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving beta-estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Determinants of axial bone loss in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Bone density determinants in elderly women: a twin study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Testosterone levels during systemic and inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Alcohol, cytokines, and estrogen in the control of bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Exercise for female osteoporosis. A systematic review of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Relationship between exercise and bone mineral density among over 5,000 women aged 40 years and above

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Cigarette smoking and bone mineral density in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Cigarette smoking, sex hormones and bone density in women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Differential effects of endocrine dysfunction on the axial and the appendicular skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Isolated Skeletal Involvement in Cushing's Syndrome Response to Therapy*

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Quantitative microradiographic study of bone remodeling in Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Increased bone density in patients on steroids with etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intermittent Intravenous Pamidronate: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Prevention of Corticosteroid-Induced Osteoporosis with Alendronate in Sarcoid Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant-cell arteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Salmon calcitonin in the therapy of corticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Possible prevention and treatment of steroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Glucocorticoid cytosol binding in exercise-induced sparing of muscle atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Initiating regular exercise protects against muscle atrophy from glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Transient decrease in osteocalcin and markers of type 1 collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980011-6

7 January 2021

10.1016/S0049-0172(00)80011-6

Identifiers

DOI

1 reference

29 July 2017

1 reference